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Leflunomide is a novel immunomodulatory drug prescribed for treating rheumatoid arthritis. It inhibits the activity of
protein tyrosine kinases anddihydroorotate dehydrogenase, a rate-limiting enzyme in the pyrimidine nucleotide synthesis
pathway. Here, we report that A77 1726, the activemetabolite of leflunomide, inhibited the phosphorylation of ribosomal
protein S6 and two other substrates of S6K1, insulin receptor substrate-1 and carbamoyl phosphate synthetase 2, in an
A375melanoma cell line. A77 1726 increased the phosphorylation of AKT, p70 S6 (S6K1), ERK1/2, andMEK through the
feedback activationof the IGF-1 receptor–mediated signaling pathway. In vitro kinase assay revealed that leflunomide and
A771726 inhibitedS6K1activitywith IC50 valuesof approximately 55 and80μM, respectively. Exogenousuridinepartially
blocked A77 1726–induced inhibition of A375 cell proliferation. S6K1 knockdown led to the inhibition of A375 cell
proliferation but did not potentiate the antiproliferative effect of A77 1726. A77 1726 stimulated bromodeoxyuridine
incorporation inA375cells but arrested the cell cycle in theSphase,whichwas reversedby additionof exogenousuridine
or by MAP kinase pathway inhibitors but not by rapamycin and LY294002 (a phosphoinositide 3-kinase inhibitor). These
observations suggest that A77 1726 accelerates cell cycle entry into the S phase throughMAP kinase activation and that
pyrimidine nucleotide depletion halts the completion of the cell cycle.Our study identified a novelmolecular target of A77
1726 and showed that the inhibition of S6K1 activity was in part responsible for its antiproliferative activity. Our study also
provides a novel mechanistic insight into A77 1726–induced cell cycle arrest in the S phase.
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The phosphoinositide 3-kinase (PI3K) pathway is frequently
activated in human cancers and plays essential roles in cell
proliferation, apoptosis, protein synthesis, and metabolism. The
PI3K pathway is activated through amplification or mutations of the
genes encoding protein kinases or deletion of the tumor suppressor
phosphatase and tensin homolog [1]. In recent years, extensive efforts
in developing the inhibitors of the PI3K pathway as novel therapeutic
agents to treat certain types of cancer in which the PI3K pathway is
hyperactivated have been thwarted by unacceptable toxicity or poor
pharmacokinetics [2,3]. So far, only everolimus and temsirolimus,
two rapamycin analogs that inhibit the mammalian target of
rapamycin (mTOR), have been shown to be beneficial in several
cancer types [2,3].
Leflunomide (Arava) is an immunomodulatory drug for the
treatment of rheumatoid arthritis. Early studies revealed that A77
1726 has two biochemical activities, the inhibition of tyrosine
phosphorylation and inhibition of pyrimidine nucleotide synthesis
[4–11]. The ability of A77 1726 to inhibit the activity of dihydroorotate
dehydrogenase (DHO-DHase), a rate-limiting enzyme in pyrimidine
nucleotide synthesis, is about 10 to 100 times more potent than its
ability to inhibit the activity of protein tyrosine kinases such as p56lck,
p59fyn, and PDGF receptor [4–8]. The inhibition of pyrimidine
nucleotide synthesis is thought to be the mechanism of action of
leflunomide [12,13]. White et al. [14] reported that leflunomide
inhibits transcriptional elongation of the genes involved in self-renewal
of neural progenitor cells through inhibition of DHO-DHase activity.
These investigators further demonstrated that leflunomide at low doses
cooperates with PLX4720, a B-Raf kinase inhibitor, to effectively
inhibit melanoma cell proliferation and tumor growth [14]. Our early
studies using a lymphadenopathy and autoimmune disease model in
MRL/MpJ-lpr/lpr mice and a tumor xenograft model demonstrated
that the immunosuppressive and antitumor activities of leflunomide are
largely independent of the pyrimidine nucleotide synthesis pathway
[4,5] since uridine co-administration with leflunomide normalized
pyrimidine nucleotide levels in tumor tissues but did not antagonize the
antitumor activity of leflunomide in two xenograft models [5]. Those
studies suggest that leflunomide may exert its antiproliferative and
immunosuppressive activity [4,5] independent of its inhibitory effect on
pyrimidine nucleotide synthesis.
S6K1 is a member of serine/threonine protein kinases A, G, and C
family, including AKT and mTOR. S6K1 is one of the predominant
effectors of the mTOR complex 1 (mTORC1; Figure 7) [15]. The
mTORC1-S6K1 pathway plays an important role in regulating
protein synthesis, cell growth, metabolism, and aging [15]. S6K1 is
overexpressed or activated in primary liver neoplasms, ovarian
cancers, and many other types of malignancy due to the gene
mutations in the PI3K pathway [15,16]. S6K1 gene amplification
occurs in 10% of breast cancers and is associated with a poor
prognosis [17]. S6K1 serves as a biomarker to predict breast cancer in
response to rapamycin [18]. Two recent studies demonstrated that
S6K1 phosphorylates carbamoyl phosphate synthetase 2 (CAD), a
rate-limiting enzyme involved in pyrimidine nucleotide synthesis, and
stimulates its enzymatic activities [19,20]. There have been
considerable efforts in search for the specific inhibitors to target this
important player in the mTORC1-S6K1 pathway. Numerous small
molecule compounds that inhibit S6K1 alone or both S6K1 and AKT
are at the early stage of clinical trials for anticancer therapy [15]. Here,
we report that leflunomide and its active metabolite, A77 1726, arethe inhibitors of S6K1 and that the inhibition of S6K1 activity
contributes to its antiproliferative effect on A375 tumor cells.
Experimental Procedures
Reagents
Leflunomide and A77 1726 were kindly provided by Cinkate
Corporation (Oak Park, IL). PPP was purchased from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). U0126, LY294002, and
rapamycin were purchased from Cell Signaling Technology (Danvers,
MA). OSI-906 was purchased from Selleckchem.com (Houston, TX).
Antibodies against ERK1/2, MEK1/2, Raf-1, p90 RSK, GSKα/β,
4E-BP, PDK1, AKT, mTOR, S6K1, and S6 and their corresponding
phosphor antibodies including ERK1/2T202/Y204, MEK1/2S217/S221,
Raf-1S338, p90 RSKT356/S360, GSKα/βS21/9, 4E-BPT37/46, PDKS241,
AKTS473, AKTT308, mTORS2448, S6K1T389, S6S235/236 insulin
receptor substrate-1S1101 (IRS-1S1101), and CADS1859 were purchased
from Cell Signaling Technology.
Cell Lines
A375 cells are a melanoma cell line with BRAFV600E mutation
and wild-type phosphatase and tensin homolog/PI3KC and p53.
MCF-7 cells are an estrogen-positive breast cancer cell line with
PI3KC mutation but with wild-type p53. BT-20 cells are a breast
cancer cell line with PI3KC mutations (P539R and H1047R) and p53
(K132Q) mutation. A375 and BT-20 cells were cultured in
complete Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% FBS, streptomycin (100 μg/ml) and penicillin
(100 units/ml), and L-glutamine (2 mM). MCF-7 cells were grown
in the complete MEM medium supplemented with 10% FBS,
streptomycin and penicillin, L-glutamine, non-essential amino acids
(1×), Hepes buffer (10 mM), and sodium pyruvate (1 mM). All
three cell lines were purchased from American Tissue Culture
Collection (Manassas, VA).
Western Blot
Cells seeded in six-well plates were harvested and lysed inNP-40 lysis
buffer [50 mMTris-HCl (pH 8.0), 150 mMNaCl, 1%NP-40, 5 mM
EDTA, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 1 mM PMSF].
After incubation on ice for 30 minutes, the cell lysates were prepared
by spinning down at 4°C, 15,000 rpm for 15 minutes. After
electrophoresis and transfer to Immobilon membrane, proteins of
interest were probed with their specific antibodies, followed by HRP-
conjugated goat anti-rabbit or anti-mouse IgG and SuperSignal
Western Pico enhanced chemiluminescence substrate (Pierce Chemical
Co, Rockford, IL).
In Vitro p70 S6 Kinase Assay
The ability of leflunomide and A77 1726 to inhibit p70 S6 kinase
assay was conducted by using an ADP-Glo Kinase assay system
(Promega Corporation, Madison, WI). Briefly, A77 1726 or
leflunomide diluted in the kinase buffer was mixed with recombinant
p70 S6 kinase (100 ng per reaction) and incubated at room
temperature for 30 minutes. Peptide substrate of p70 S6 kinase (5 μg
per reaction) and ATP (10 μM, final concentration) was added, with
a total final volume of 25 μl. After incubation for 1 hour, ADP-Glo
reagent (25 μl) was added to each reaction. After incubation for 40
minutes, kinase detection substrate (luciferin; 50 μl per reaction) was
added. After incubation for 30 minutes, luciferase activity was
measured by reading in a luminescence plate reader. The experiment
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Figure 1. Effect of A77 1726 on the PI3K and MAP kinase pathways. A375 cells seeded in a six-well plate were starved in DMEM
containing 0.5% FBS for 2 hours and treated with the indicated concentration of A77 1726 for another 2 hours (A) or treated with A77 1726
(100 μM) for the indicated time (B). Cells were harvested and analyzed for protein phosphorylation by specific antibodies as indicated.
Protein loading was monitored by stripping membrane and reprobing with antibodies against non-phosphorylated proteins.
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The data from one experiment were presented as mean ± SD.
S6K1 Knockdown
S6K1 siRNA ON-TARGETplus SMARTpool was synthesized by
Dharmacon (Lafayette, CO) and purchased from Fisher Scientific(Pittsburg, PA). This S6K1 siRNA pool containing three different
siRNAs has been previously shown to efficiently suppress S6K1
expression [21,22]. A scrambled control siRNA was purchased from
Invitrogen Life Technologies (Grand Island, NY). A375 cells seeded
in a six-well plate were transfected with siRNA using Lipofectamine
RNAiMAX (Invitrogen Life Technologies) according to the
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Figure 2.Mechanisms of A77 1726–induced feedback activation of the PI3K and MAP kinase pathways. (A) Inability of uridine to reverse
the effect of A77 1726 on the PI3K andMAP kinase pathways. A375 cells seeded in a six-well plate were starved in DMEM containing 05%
FBS for 2 hours and treated with the indicated concentration of A77 1726 in the absence or presence of uridine (200 μM) for 2 hours.
Phosphorylated and total proteins were analyzed byWestern blot as described in Figure 1. (B) In vitro S6K1 kinase assay. Leflunomide and
A77 1726 diluted at the final concentrations as indicated were premixed with S6K1 for 30 minutes, followed by the addition of peptide
substrate of S6K1 and incubation for 1 hour. S6K1 activity wasmeasured by using an ADP-Glo system. The experiment was repeated with
similar results. The data represent the mean ± SD from one experiment in triplicate. (C) The effect of the MAP kinase pathway inhibitors
on A77 1726–induced feedback activation of the PI3K and MAP kinase pathways. A375 cells seeded in six-well plates were starved in
DMEM containing 0.5% FBS for 2 hours and then pretreated with vehicle (0.1% DMSO) or the inhibitors of the MAP kinase pathway
(PLX4720, 1 μM; U0126, 10 μM) for 1 hour. Cells were then treated with A77 1726 (100 μM) or rapamycin (20 nM) as indicated for 2 hours.
Cells were harvested and analyzed for protein phosphorylation by specific antibodies as indicated. (D–F) The effect of PI3K, mTOR, and
IGF-1 receptor inhibitors on A77 1726–induced feedback activation of the PI3K and MAP kinase pathways. A375 cells seeded in six-well
plates were starved in DMEM containing 0.5% FBS for 2 hours and then pretreated with vehicle (0.1% DMSO), LY294002 (10 μM) or
rapamycin (20 nM) (D), PPP (1 μM) (E), or OSI-906 (0.2 μM) (F) for 1 hour. Cells were then treated with A77 1726 (100 μM) as indicated for
2 hours. Cells were harvested and analyzed for protein phosphorylation by specific antibodies as indicated. Protein loading wasmonitored
by stripping membrane and reprobing with antibodies against non-phosphorylated proteins.
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828 Doscas et al. Neoplasia Vol. 16, No. 10, 2014manufacturer’s instruction. After incubation for 48 hours, the cells
were harvested and analyzed for S6K1 expression and for the
phosphorylation of S6K1, AKT, S6, and CAD by Western blot.
Cell Proliferation Assay
A375 cells were seeded in 96-well plates at a density of 2000
per well in the absence or presence of indicated concentrations
of A77 1726, PLX4720, or uridine (200 μM). After incubation
for 72 hours, cell proliferation was monitored by using an
ATP-based Cell-Glo assay (Promega Corporation) following the
manufacturer’s instruction.
DNA Replication and Cell Cycle Analysis
Upon 60% confluence, A375 cells were treated with vehicle or
with indicated concentrations of A77 1726 or indicated inhibitors
for 24 hours. Cells were pulsed with 10 μM bromodeoxyuridine
(BrdU) for 2 hours. Cells were harvested and denatured with 2 N
HCl for 5 minutes at room temperature followed by neutralization
with 0.1 M borate buffer (pH 8.5). After washing and blocking
with normal mouse serum, the cells were stained with an Alexa
Fluor 488–conjugated anti-BrdU monoclonal antibody (BD
Biosciences, San Jose, CA), followed by analysis in a Becton
Dickson FACScan flow cytometer. Alexa Fluor 488–conjugated0
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Figure 3. Antiproliferative effect of A77 1726. A375 cells were
seeded in 96-well plates (2000 cells per well) and incubated at the
indicated concentrations of A77 1726 for 72 hours in the absence
or presence of various concentrations of PLX4720 with (A) or
without uridine (200 μM) (B). Cell proliferation was analyzed by an
ATP-based Cell-Glo assay. Data from one representative of three
experiments with similar results were shown.mouse IgG was included as a control. For cell cycle analysis, the
cells were harvested and fixed in 2 ml of cold 70% ethanol in
phosphate-buffered saline (PBS) overnight at 4°C. Fixed cells were
then washed three times with PBS and treated with RNaseA
(100 μg/ml in 0.5 ml of PBS). After incubation at room
temperature for 30 minutes, cells were stained with 2.5 μl of
propidium iodide (10 mg/ml) and immediately analyzed for DNA
content in a Becton Dickson FACScan flow cytometer.
Statistical Analysis
The differences in A375 cell proliferation between different
treatment groups were statistically analyzed by using an unpaired
Student's t test. A P value of b .05 was considered statistically
significant. All statistics was performed with SigmaPlot 11 software
(Systat Software Inc., Richmond, CA).
Results
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Figure 4. Effect of S6K1 knockdown on feedback PI3K pathway
activation and cell proliferation. (A) S6K1 knockdown. A375 cells
seeded in a six-well plate were transfected with scrambled or S6K1
siRNA (2.5 nmol each). After incubation for 48 hours, the cells were
harvested and analyzed for S6K1 expression and phosphorylation
of the indicated proteins by Western blot. (B) The effect of S6K1
knockdown on cell proliferation. A375 cells seeded in a 96-well
plate were transfected with a scrambled control siRNA or S6K1
siRNA. After incubation overnight, the cells were incubated in the
absence or presence of A77 1726 (100 or 200 μM) for 72 hours and
analyzed for cell proliferation by an ATP-based Cell-Glo assay. Data
represent the mean ± SD from one of two experiments in triplicate
with similar results. *P b .05, compared to control siRNA-transfected
A375 cells.
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and then treated with the indicated concentrations of A77 1726
for another 2 hours. A77 1726 strongly induced ERK1/2T202/204
and MEKS217/S221 phosphorylation (Figure 1A) but had no effect on
Raf-1 phosphorylation (data not shown) in A375 cells. Of note, A77
1726 at 50 μM always induced MEK phosphorylation more effectively
than ERK phosphorylation in multiple experiments. Induction of
ERK1/2 phosphorylation was similarly achieved in A77 1726–treated
A375 cells cultured in the medium containing 10% FBS (data not
shown). A77 1726 strongly induced phosphorylation of AKTS473 and
S6K1T389 in a dose-dependentmanner but had no or onlyminimal effect
on phosphorylation of PDK1S241, mTORS244, as well as GSKα/βS21/9,
p90 RSKT353/356, and 4E-BPT37/46 (data not shown). In contrast, A77
1726 inhibited the phosphorylation of ribosomal protein S6S235/S236 in
a dose-dependent manner (Figure 1A). Recent studies have shown
that CAD, a rate-limiting enzyme involved in pyrimidine nucleotide
synthesis, is phosphorylated by S6K1 at Ser-1859 [19,20]. As shown in
Figure 1A, A77 1726 inhibited CAD phosphorylation in a dose-
dependent manner. In addition, S6K1 phosphorylates IRS-1 at Ser-1101
and suppresses IGF-1 receptor–mediated activation of the PI3K pathway
[23]. A77 1726 inhibited IRS-1S1101 in a dose-dependent manner
(Figure 1A). Inhibition of S6S235/236 phosphorylation was also observed
in BT-20 and MCF-7 cells (data not shown). Similar results were
obtained with leflunomide (data not shown). The stimulatory effect on
AKTS473 and S6K1T389 phosphorylation and the inhibitory effect of
A77 1726 on S6S235/236 phosphorylation were very rapid and long-
lasting, within a few minutes after exposure to A77 1726 and lasted for
up to 48 hours (Figure 1B).
Feedback Activation of the PI3K and MAP Kinase Pathways
by A77 1726 Is Independent of Its Inhibitory Effect on
Pyrimidine Nucleotide Synthesis
A77 1726 inhibits pyrimidine nucleotide synthesis [12]. To rule
out the possibility that the activation of PI3K and MAP kinase
pathways was due to pyrimidine nucleotide depletion, we tested
whether exogenous uridine affected the phosphorylation of several
signaling molecules in the MAP and PI3K pathways. As shown in
Figure 2A, uridine (200 μM) did not block A77 1726–induced
phosphorylation of ERK1/2T202/Y204, MEK1/2S217/S221, and
AKTS473, suggesting that the effect of A77 1726 on the MAP and
PI3K pathways is not mediated through its inhibitory effect on
pyrimidine nucleotide synthesis.
Validating S6K1 as a Molecular Target of A77 1726
The ability of A77 1726 to inhibit S6, IRS-1, and CAD but to
increase AKT and S6K1 phosphorylation strongly suggests that S6K1
is the molecular target of A77 1726. To prove this, we conducted an
in vitro kinase assay to determine if leflunomide and A77 1276
directly inhibited S6K1 activity. Indeed, leflunomide and A77 1726
inhibited the activity of recombinant S6K1 in a dose-dependentFigure 6. Effect of exogenous uridine and MAP kinase pathway inh
uridine to A77 1726–induced DNA synthesis. A375 cells were treate
presence of uridine (200 μM) for 22 hours. After pulsing with BrdU
incorporation by staining with an Alexa Fluor 488–conjugated anti-Brd
of theMAP kinase pathway inhibitors (B) and the PI3K pathway inhibito
treated with A77 1726 (100 μM) in the presence of 0.1% DMSO, PLX4
(10 μM) (C). After incubation for 22 hours, the cells were pulsed with
incorporation and analyzed for cell cycle in a flow cytometer as descmanner, with IC50 values of approximately 55 and 80 μM,
respectively (Figure 2B).
The Effect of the MAP Kinase Pathway Inhibitors on A77
1726–Induced MAP Kinase Pathway Feedback Activation
The inhibitors of the MAP kinase pathway were used to gain the
mechanistic insight into how A77 1726 induced MAP kinase
pathway activation in A375 cells. PLX4720 (a Raf kinase inhibitor)
blocked A77 1726–induced phosphorylation of ERK1/2T202/Y204
and MEK1/2S217/S221. U0126 (a MEK inhibitor) blocked A77
1726–induced ERK1/2T202/Y204 phosphorylation but had no effect
on MEK phosphorylation (Figure 2C). Interestingly, inhibition of the
MAP kinase pathway by PLX4720 and U0126 enhanced AKTS473
phosphorylation in A77 1726–treated A375 cells.
The Effect of the PI3K Pathway and IGF-1 Receptor Inhibitors
on A77 1726–Induced PI3K Pathway Feedback Activation
A prior study demonstrated that rapamycin-mediated feedback
activation of the MAP kinase pathway is mediated through
PI3K-induced Ras activation in MCF-7 cells [24]. Here, we tested
whether PI3K was involved in A77 1726–induced MAP kinase
pathway activation. LY294002, a PI3K inhibitor, had little effect on
A77 1726–induced phosphorylation of MEK and ERK1/2 but largely
blocked A77 1726–induced AKTS473 phosphorylation (Figure 2D). It
is well established that S6K1 phosphorylates IRS-1S1101 and suppresses
the IGF-1 receptor–mediated activation of the PI3K pathway (Figure 7)
[2]. We tested whether inhibition of IGF-1 receptor tyrosine kinase
activity led to the suppression of A77 1726–induced PI3K and MAP
kinase pathway activation. As shown in Figure 2E, PPP, a specific
inhibitor of IGF-1 receptor, had no effect on base levels of ERK1/2T202/
Y204, MEK1/2S217/S221, and AKTT473 phosphorylation and largely
blocked A77 1726–induced AKTS473 phosphorylation. OSI-906, a
second IGF-1 receptor inhibitor, blocked A77 1726–induced AKTS473
and MEK1/2S217/S221 phosphorylation (Figure 2F). PPP and OSI-906
had no or minimal effect on A77 1726–induced ERK1/2T202/Y204
phosphorylation.
Antiproliferative Effect of A77 1726
We next tested whether the antiproliferative activity of A77 1726
on A375 cells was mediated by its inhibitory effect on pyrimidine
nucleotide synthesis. A77 1726 at the concentration of 50, 100, and
200 μM inhibited the proliferation of A375 by 39%, 65%, and 88%,
respectively (Figure 3A), with an IC50 value of approximately 65 μM.
In the presence of exogenous uridine, A77 1726 at the concentration
of 50, 100, and 200 μM inhibited the proliferation of A375 by 17%,
24%, 70%, respectively. Thus, uridine partially blocked the inhibitory
effect of A77 1726 (Figure 3B). PLX4720 at 1 nMby itself had no effect
on untreated or A77 1726–treated A375 cell proliferation (Figure 3A).
PLX4720 (100 or 500 nM) by itself inhibited A375 proliferation
(Figure 3A). When used in combination with A77 1726 in the absenceibitors on A77 1726–stimulated BrdU incorporation. (A) Effect of
d with the indicated concentration of A771726 in the absence or
(10 μM) for 2 hours, cells were harvested and analyzed for BrdU
Umonoclonal antibody followed by flow cytometry. (B and C) Effect
rs (C) on A77 1726–stimulated BrdU incorporation. A375 cells were
720 (1 μM), U0126 (10 μM) (B) or rapamycin (20 nM), and LY294002
BrdU for 2 hours. Single-cell suspensions were stained for BrdU
ribed in A.
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Figure 7. Mechanisms of action of A77 1726 on cell cycle progress
and proliferation. A77 1726 inhibits the activity of S6K1, leading to the
feedback activation of the PI3K and MAP kinase pathways through
IGF-1 receptor. MAP kinase activation accelerates the entry of cell
cycle into the S phase. However, due to the depletion of pyrimidine
nucleotide pools through the inhibition of DHO-DHase and CAD
activity, DNA replication and chromosome duplication cannot be
completed, leading to the stall of cell cycle in the S phase. A77 1726
suppresses cell proliferation by inhibitingDNAand protein synthesis.
In some types of cancer, A77 1726 may also inhibit cell proliferation
by inhibiting the activity of protein tyrosine kinases.
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proliferation of A375 cells (Figure 3).
Effect of S6K1 Knockdown on the PI3K Signaling Pathway
and Cell Proliferation
To confirm that inhibition of S6K1 activity contributed to the
antiproliferative effect of A77 1726, we tested if S6K1 knockdown led
to the suppression of cell proliferation. As shown in Figure 4A, S6K1
transfection effectively suppressed S6K1 expression in A375 cells,
leading to decreased S6 and CAD phosphorylation but increased
AKTS473 phosphorylation. S6K1 knockdown alone significantly
decreased A375 cell proliferation by 20% (Figure 4B). A77 1726 at
concentrations of 100 and 200 μM inhibited the proliferation of
control siRNA-transfected A375 cells by 23% and 48%, respectively.
A77 1726 at concentrations of 100 and 200 μΜ reduced the
proliferation of S6K1 siRNA-transfected A375 cells by 9% and 37%,
respectively, compared to that in untreated S6K1 siRNA-transfected
A375 cells. Combination of S6K1 knockdown and A77 1726 did notachieve an additive antiproliferative effect, suggesting that A77 1726
inhibits A77 1726 proliferation in part by suppressing S6K1 activity.
Effect of A77 1726 on Cell Cycle and DNA Synthesis
We next tested whether the antiproliferative effect of A77 1726 was
mediated by arresting cell cycle progress. A375 cells were treated with
the indicated concentration of A77 1726 and/or uridine for 24 hours
and analyzed for cell cycle by propidium iodide staining. As shown in
Figure 5A, A77 1726 at 50 μMwas sufficient to arrest cell cycle in the S
phase. Consistent with this observation, a significantly higher number
of cells treated with 50 μM were labeled with BrdU than those treated
with A77 1726 at 100 or 200 μM (Figure 6A). Uridine alone had little
effect in cell cycle arrest but normalize cell cycle in A375 cells treated
with A77 1726 at three different concentrations (Figure 5A). BrdU
labeling revealed that uridine blocked the increase of BrdU
incorporation in A375 cells mediated by A77 1726 (Figure 6A).
We then tested whether the inhibitors of the MAP kinase pathways
affected A77 1726–induced DNA synthesis. As shown in Figure 5B,
PLX 4720 (1 μM) and U0126 (10 μM) led to the arrest of the cell
cycle in the G1 phase in untreated or A77 1726–treated A375 cells.
BrdU labeling revealed that PLX 4720 (1 μM) and U0126 (10 μM)
alone were able to completely block DNA replication in A375 cells in
the absence or presence of A77 1726 (Figure 6B). These results
suggest that A77 1726 treatment led to accelerated DNA synthesis
through MAP kinase activation.
Finally, we tested the inhibitors of the PI3K pathway on A77
1726–induced cell cycle progress and DNA replication. Rapamycin
or LY249002 alone did not lead to the arrest of cell cycle in the G1
phase (Figure 5C) and was unable to promote cell cycle progress of
A77 1726–treated A375 cells. BrdU labeling revealed that LY294002
or rapamycin alone did not significantly affect DNA synthesis but
slightly attenuated A77 1726–stimulated DNA synthesis (Figure 6C).
These observations suggest that A77 1726–induced cell cycle arrest
and DNA synthesis is independent of its effect on the feedback
activation of the PI3K pathway.
Discussion
Several prior studies have demonstrated that A77 1726 is capable of
inhibiting the PI3K pathway. For example, Baumann et al. [25]
reported that the phosphorylation of AKTT308, AKTS473, 4E-BPT37/46,
and S6K1T389 is inhibited inH929 andOPM-2myeloma cell lines after
incubation for 24 and 48 hours with A77 1726 (200 μM). Liacini et al.
[26] reported that A77 1726 weakly inhibits PDK1 and AKT
phosphorylation in a renal CCD1105 cell line and primary human
tubular cells, suggesting that A77 1726 may target a kinase upstream of
PDK1 or AKT. Sawamukai et al. [27] reported that A77 1726 at 100
and 200 μM inhibits c-Kit ligand-induced PDKS241, AKTT308, and
GSK3βS9 in human mast cells. While these studies showed that the
PI3K signaling pathway is suppressed by A77 1726, themolecular target
of A77 1726 has remained elusive. Our present study demonstrated the
ability of A77 1726 to inhibit the phosphorylation of three substrates
(S6, CAD, and IRS-1) of S6K1 and the ability of A77 1726 to directly
inhibit S6K1 activity in an in vitro kinase assay. Our studies identified
S6K1 as a novel molecular target of A77 1726.
IRS-1 is an adaptor protein that interacts with the IGF-1 or insulin
receptor and plays a critical role inmediating insulin- and IGF-1–induced
activation of the PI3K [28]. S6K1 phosphorylates IRS-1 at Ser-1101 and
suppresses PI3K activation. Our study demonstrated the inhibition of
IRS-1S1101 phosphorylation by A77 1726 and suggests that A77 1726
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IGF-1 receptor–mediated signaling pathway. Indeed, two inhibitors
of the IGF-1 receptor tyrosine kinase, PPP and OSI-906, blocked
A77 1726–induced feedback activation of the PI3K pathway. We
speculate that A77 1726 does not directly stimulate the IGF-1
receptor tyrosine kinase activity but rather enhances the IGF-1
receptor/IRS-1–mediated PI3K activation. Consistent with this
notion, several prior studies suggest that rapamycin induces AKT
feedback activation in an IGF-1 receptor–dependent manner [29–31].
Furthermore, two S6K1 inhibitors induce feedback activation of the
PI3K pathway by inhibiting IRS-1 phosphorylation [32,33].
Though IRS-1 is also required for IGF-1 receptor–mediated
activation of the MAP kinase pathway, the underlying mechanisms
are less clear [28]. Cook et al. reported that A77 1276 activates Raf-1
kinase in a BON human gastrointestinal carcinoid cell line [34]. Our
present study showed that A77 1726 induced ERK1/2 and MEK
phosphorylation in A375 cells (Figure 1) but had no effect on Raf-1
phosphorylation (data not shown). PPP and OSI-906 had no effect on
the basal level ofMEK and ERK phosphorylation. These two inhibitors
weakly inhibited A77 1726–induced MEK phosphorylation but had
minimal or no effect on ERK phosphorylation. Interestingly, Carracedo
et al. [24] reported that rapamycin induces feedback activation of the
MAP kinase pathway through Ras. It is likely that A77 1726–induced
MEK and ERK phosphorylation may be mediated through the IGF-1
receptor and/or Ras.
The finding that A77 1726 induced the PI3K and MAP kinase
pathway feedback activation through the IGF-1 receptor has very
important clinical implications. Leflunomide treatment alone may not
have strong anticancer effect due to the feedback activation of both
PI3K and MAP kinase pathways in some types of cancer. However,
leflunomide in combination with an IGF-1 receptor inhibitor or with
the PI3K and/or MAP kinase inhibitors may achieve a synergistic
effect. Leflunomide in combination with low-dose everolimus leads to
the control of Kaposi’s sarcoma in a case report [35]. White et al. [14]
reported that leflunomide in combination with PLX4720 achieved a
synergistic effect in a melanoma xenograft mouse model.
Prior studies showed that A77 1726 arrests cell cycle progress in the
S phase in human gastrointestinal carcinoid [34], prostate, and
cutaneous squamous cancer cell lines [36]. Huang et al. [37]
suggested that cell cycle arrest in the S phase in K562 cells by A77
1726 is mediated by nucleotide depletion that relies on mutant p53.
Our present study demonstrated that A77 1726 stimulated BrdU
incorporation but arrested cell cycle arrest in the S phase in wild-type
p53 A375 cells. We postulate that activation of the MAP kinase
pathway stimulates the cell cycle entry into the S phase. However,
depletion of pyrimidine nucleotide pools in A77 1726–treated cells
prevents the completion of DNA synthesis and chromosomal
duplication (Figure 7), leading to the stall of the cell cycle in the
S phase. In support of this notion, MAP kinase pathway inhibitors
(U0126 and PLX2720) arrested the cell cycle in the G1 phase in A77
1726–treated A375 cells. It should be noted that A77 1726 arrests cell
cycle progress in the G1 phase in lymphocytes [8] and in several
myeloma cell lines [25], probably due to the lack of IGF-1 receptor
and/or the lack of the MAP kinase activation in these cells.
The antiproliferative activity of A77 1726 in lymphocytes and
tumor cells has been well documented. However, the underlying
molecular mechanisms are not fully understood. Depletion of
pyrimidine nucleotide pools in vitro in cell culture by A77 1726,
particular at low concentrations (b50 μM), is largely responsible forits antiproliferative activity. Uridine was able to partially block the
inhibitory effect of A77 1726 used at 50 or 100 μM on cell
proliferation but had little effect to reverse the ability of A77 1726 at
200 μM to inhibit cell proliferation. These results suggest that A77
1726 used at high concentrations largely exerts its antiproliferative
activity independent of its anti-pyrimidine mechanism. A recent
study demonstrated that leflunomide but not A77 1726 functions as
an agonist of aryl hydrocarbon receptor to contribute to its
antiproliferative activity [38], though underlying mechanisms are
still not fully understood. In the present study, we demonstrated that
both leflunomide and A77 1726 inhibited S6K1 activity. Since its
downstream effector, ribosomal protein S6, plays a critical role in
protein synthesis, A77 1726 may exert its antiproliferative activity in
part by inhibiting S6 kinase phosphorylation and activation. In
support of this notion, S6K1 knockdown significantly inhibited A375
cell proliferation, and S6K1 in combination with A77 1726 did not
reach an additive effect.
The IC50 values of leflunomide and A77 1726 to inhibit S6
phosphorylation in cell culture were approximately between 50 and
75 μM, consistent with the results obtained from in vitro kinase assay
revealing the IC50 values of leflunomide and A77 1726 to inhibit
S6K1 approximately at 55 and 80 μM, respectively. A77 1726 or
leflunomide may also inhibit S6K2 but is unlikely able to inhibit
other serine/threonine protein kinases A, G, and C such as AKT and
mTOR. The IC50 values of leflunomide and A77 1726 required to
inhibit S6K1 are physiologically relevant. The pharmacokinetics of
leflunomide favorably fit its potential use in oncology. Plasma
concentrations of A77 1726 in rheumatoid arthritis patients treated
with leflunomide (20 mg/day) can reach 200 μM [39]. The serum
concentrations of A77 1726 in mice treated with leflunomide at a
dose of 35 mg/kg had a remarkably long half-life of 15 hours. A77
1726 peaks at 500 μM within 4 hours and remains at 250 μM at 24
hours after a single dose of 35 mg/kg leflunomide [40]. Both these
concentrations are sufficient to inhibit S6K1 activity. We anticipate
that the dose of leflunomide used in preclinical studies and in patients
will allow the concentration of A77 1726 in tumor tissue to exceed its
IC50 values and to inhibit S6K1 activity.
In summary, our study demonstrated the ability of leflunomide
and its active metabolite to inhibit S6K1 activity and to induce the
feedback activation of the PI3K and MAP kinase pathways (Figure 7).
We further showed that the feedback activation of the MAP kinase
pathway by A77 1726 led to the accelerated S cell cycle entry and
DNA replication; however, depletion of pyrimidine nucleotide
synthesis through direct inhibition of DHO-DHase activity as well
as indirect inhibition of CAD activity stalled the cell cycle in the S
phase (Figure 7). A77 1726 inhibited cell proliferation in part by
inhibiting S6K1 activity.References
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